138 related articles for article (PubMed ID: 10963181)
41. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.
Kameyama R; Yamamoto Y; Izuishi K; Takebayashi R; Hagiike M; Murota M; Kaji M; Haba R; Nishiyama Y
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):382-8. PubMed ID: 18985344
[TBL] [Abstract][Full Text] [Related]
42. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
Peterson JJ
Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
[TBL] [Abstract][Full Text] [Related]
43. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
Conrad GR; Sinha P
Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT.
Hoshi M; Takada J; Oebisu N; Hata K; Ieguchi M; Nakamura H
Arch Orthop Trauma Surg; 2012 Nov; 132(11):1561-8. PubMed ID: 22825642
[TBL] [Abstract][Full Text] [Related]
45. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J
Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620
[TBL] [Abstract][Full Text] [Related]
46. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II.
Hamada K; Tomita Y; Qiu Y; Zhang B; Ueda T; Myoui A; Higuchi I; Yoshikawa H; Aozasa K; Hatazawa J
Ann Nucl Med; 2008 Oct; 22(8):699-705. PubMed ID: 18982473
[TBL] [Abstract][Full Text] [Related]
47. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography.
Lucas JD; O'Doherty MJ; Cronin BF; Marsden PK; Lodge MA; McKee PH; Smith MA
Br J Surg; 1999 Apr; 86(4):550-6. PubMed ID: 10215835
[TBL] [Abstract][Full Text] [Related]
48. Role of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography in the management of bone and soft-tissue metastases.
Yanagawa T; Shinozaki T; Iizuka Y; Takagishi K; Watanabe H
J Bone Joint Surg Br; 2010 Mar; 92(3):419-23. PubMed ID: 20190315
[TBL] [Abstract][Full Text] [Related]
49. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
[TBL] [Abstract][Full Text] [Related]
50. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
[TBL] [Abstract][Full Text] [Related]
51. Schwannoma of the extremities: the role of PET in preoperative planning.
Ahmed AR; Watanabe H; Aoki J; Shinozaki T; Takagishi K
Eur J Nucl Med; 2001 Oct; 28(10):1541-51. PubMed ID: 11685498
[TBL] [Abstract][Full Text] [Related]
52. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
Morris MJ; Akhurst T; Osman I; Nunez R; Macapinlac H; Siedlecki K; Verbel D; Schwartz L; Larson SM; Scher HI
Urology; 2002 Jun; 59(6):913-8. PubMed ID: 12031380
[TBL] [Abstract][Full Text] [Related]
53. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions.
Dimitrakopoulou-Strauss A; Strauss LG; Heichel T; Wu H; Burger C; Bernd L; Ewerbeck V
J Nucl Med; 2002 Apr; 43(4):510-8. PubMed ID: 11937595
[TBL] [Abstract][Full Text] [Related]
54. The role of 18F-FDG PET/CT in the metabolic characterization of lung nodules in pediatric patients with bone sarcoma.
Cistaro A; Lopci E; Gastaldo L; Fania P; Brach Del Prever A; Fagioli F
Pediatr Blood Cancer; 2012 Dec; 59(7):1206-10. PubMed ID: 22745027
[TBL] [Abstract][Full Text] [Related]
55. Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis.
Li YJ; Dai YL; Cheng YS; Zhang WB; Tu CQ
Eur J Surg Oncol; 2016 Aug; 42(8):1103-14. PubMed ID: 27189833
[TBL] [Abstract][Full Text] [Related]
56. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
[TBL] [Abstract][Full Text] [Related]
57. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
Sahlmann CO; Siefker U; Lehmann K; Meller J
Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
[TBL] [Abstract][Full Text] [Related]
58. PET imaging of blood flow and glucose metabolism in localized musculoskeletal tumors of the extremities.
Lindholm P; Sutinen E; Oikonen V; Mattila K; Tarkkanen M; Kallajoki M; Aro H; Böhling T; Kivioja A; Elomaa I; Minn H
Nucl Med Biol; 2011 Feb; 38(2):295-300. PubMed ID: 21315286
[TBL] [Abstract][Full Text] [Related]
59. Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology.
Farid K; Poullias X; Alifano M; Regnard JF; Servois V; Caillat-Vigneron N; Petras S
Nucl Med Commun; 2015 Jul; 36(7):722-7. PubMed ID: 25793929
[TBL] [Abstract][Full Text] [Related]
60. Musculoskeletal Pitfalls on Fluorodeoxyglucose F 18 PET-Computed Tomography: Pictorial Review.
Asadoorian M; Matcuk GR; Patel DB; Tomasian A; Wassef HR; White EA
PET Clin; 2018 Oct; 13(4):587-607. PubMed ID: 30219190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
